PP258 - TEDUGLUTIDE REDUCES HOME PARENTERAL NUTRITION VOLUME AND IMPROVES PATIENT REPORTED OUTCOMES: DATA FROM A NATIONAL REGISTRY IN BELGIUM

PP258

TEDUGLUTIDE REDUCES HOME PARENTERAL NUTRITION VOLUME AND IMPROVES PATIENT REPORTED OUTCOMES: DATA FROM A NATIONAL REGISTRY IN BELGIUM

S. Vrancken^1,2,*, M. Arvanitakis³, K. Geboers², L. Timmermans², N. Lauwers², A. Ballarin³, H. De Schepper⁴, A. Hadefi³, A. Verbiest^1,2, L. Wauters^1,2, T. Vanuytsel^1,2

¹Translational Research Center for Gastrointestinal Disorders (TARGID), University of Leuven, ²Leuven Intestinal Failure and Transplantation Center (LIFT), University Hospitals Leuven, Leuven, ³Department of Gastroenterology, Hôpital Erasme, Hôpital Universitaire de Bruxelles, Brussels, ⁴Department of Gastroenterology, University Hospital Antwerp, Edegem, Belgium

Rationale: The glucagon-like peptide 2 analog, teduglutide, is available in Belgium since 2021 for patients with short bowel syndrome related intestinal failure (SBS-IF), who depend on home parenteral nutrition (PN). It enhances spontaneous adaptation, thereby allowing reduction of PN. Our database monitors its real-world effect in the Belgian population.

Methods: In 2021, a prospective registry including all Belgian adult patients with teduglutide was started with data collection at baseline, 3, 6 and 12 months. Teduglutide responders were defined as a ≥20% weekly PN volume reduction in patients with jejunostomy (type 1) at T6 and in patients with colon-in-continuity (type 2/3) at T12.
The treatment effect was assessed with Wilcoxon signed rank tests, with 0.05 significance level.

Results: Twenty adult patients (14 female) were included, of which 8 with Crohn’s disease, 8 with intestinal ischemia and 4 with other underlying causes. In patients with type 1 anatomy, 5/8 (62.5%) were responders.The other 3 patients stopped treatment. All 8 patients with type 2/3 anatomy, who reached T12 were responders (100%). Three patients have not reached T12 yet and 1 patient died at T6 due to recurrent mesenteric ischemia.
The effect of teduglutide on PN is shown in figure 1.
Eighty-four adverse events were reported in 19 patients. Sixty-nine were attributable to teduglutide, of which 5 were severe, including 4 hospitalizations (2 for biliary problems and 2 for (sub)obstruction).
Teduglutide also improved patient-perceived health at T12 with 8/13 patients (61.5%) indicated “much” (n=5) or “very much” (n=3) improved health. One patient reported “very much worse” health and stopped teduglutide due to no effect.

Image:

Conclusion: Teduglutide significantly reduced the weekly PN volume and calory content at each time point and improved the patient-perceived health in this real-world study from Belgium.

Disclosure of Interest: S. Vrancken Grant / Research Support from: Takeda, M. Arvanitakis Other: Speakers fee from Takeda, K. Geboers: None declared, L. Timmermans: None declared, N. Lauwers Consultant for: Takeda, A. Ballarin: None declared, H. De Schepper: None declared, A. Hadefi Other: Speakers fee from Takeda, A. Verbiest: None declared, L. Wauters: None declared, T. Vanuytsel Grant / Research Support from: Takeda, Consultant for: Takeda, Other: Speakers fee from Takeda